400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / Epigenetics / PARP / Stenoparib
CAS No.: 1140964-99-3
Synonyms: 2X-121
E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2 and enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors.
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT01618136 | Malignant Solid Tumour ... more >> Ovarian Cancer Triple Negative Breast Cancer Advanced Melanoma B-cell Malignancy, Low-grade Collapse << | Phase 1 Phase 2 | Completed | - | United Kingdom ... more >> King's College London Guy's Hospital Campus London, United Kingdom, SE1 9RT Newcastle Upon Tyne NHS Foundation Trust Newcastle Upon Tyne and Wear, United Kingdom, NE7 7DN Collapse << |
NCT02396433 | Cancer of the Breast | Phase 1 Phase 2 | Withdrawn(lack of funding.) | - | - |
实验方案
技术信息
CAS号 | 1140964-99-3 | 储存条件 |
|
|
分子式 | C18H15N5O | 运输 | 蓝冰 | |
分子量 | 317.34 | 别名 | 2X-121 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT01618136 | Malignant Solid Tumour ... more >> Ovarian Cancer Triple Negative Breast Cancer Advanced Melanoma B-cell Malignancy, Low-grade Collapse << | Phase 1 Phase 2 | Completed | - | United Kingdom ... more >> King's College London Guy's Hospital Campus London, United Kingdom, SE1 9RT Newcastle Upon Tyne NHS Foundation Trust Newcastle Upon Tyne and Wear, United Kingdom, NE7 7DN Collapse << |
NCT02396433 | Cancer of the Breast | Phase 1 Phase 2 | Withdrawn(lack of funding.) | - | - |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网